Editorial Standard
All citations on this page link to primary sources — PubMed-indexed peer-reviewed studies, official FDA and NIH documentation, registered clinical trials at ClinicalTrials.gov, and verified institutional research. ReViaWell does not cite secondary sources, marketing materials, or unverified claims. Where research is preclinical (animal models), this is clearly noted. Where human clinical data exists, it is distinguished. All compounds referenced are for research use only. Citations are provided for educational purposes — not to make therapeutic claims. About ReViaWell →
BPC-157 Research
Recovery & Repair
BPC-157 (Body Protection Compound) has one of the largest bodies of preclinical research of any research peptide currently available. Published studies span tendon repair, gut integrity, anti-inflammatory pathways, and tissue healing across multiple organ systems. All published research to date is preclinical — animal models. No large-scale human clinical trials have been completed.
BPC 157 and Standard of Care in Tendon Healing — A Systematic Review
PubMed
Systematic review examining BPC-157's role in tendon healing across multiple preclinical models. Researchers found consistent acceleration of tendon-to-bone attachment and regeneration in animal models, with proposed mechanisms involving VEGFR2 and FAK signaling pathway activation.
Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease — Wound Healing
PubMed
Review of BPC-157 application in gastrointestinal models including inflammatory bowel disease, intestinal anastomosis, and short bowel syndrome. Authors note BPC-157's unique stability in human gastric juice and its cytoprotective properties across GI tissue models.
BPC 157 and the Nitric Oxide System — Anti-Inflammatory and Cytoprotective Effects
PubMed
Examines BPC-157's interaction with the nitric oxide system as a proposed mechanism for its anti-inflammatory and cytoprotective effects. Research suggests BPC-157 may modulate NO synthesis to provide protective effects across multiple tissue types in animal models.
FDA Memorandum: BPC-157 Added to 503A/503B Difficult to Compound List (2022)
FDA
The FDA placed BPC-157 on its list of bulk drug substances that may not be used in compounding by 503A pharmacies and 503B outsourcing facilities, citing insufficient evidence of safety and effectiveness for use in compounded drug products. This action affected clinical compounding but did not alter the legal status of BPC-157 as a research compound sold under RUO designation.
Pentadecapeptide BPC 157 (PL 14736) — A Comprehensive Review of Biological Activity
PubMed
Comprehensive review of BPC-157 biological activity across organ systems. The authors (primary BPC-157 research group, Zagreb University) summarize findings across cardiovascular, neurological, musculoskeletal, and gastrointestinal models in over two decades of preclinical research. Notes the compound's unusual stability and multi-system activity profile.
TB-500 / Thymosin Beta-4 Research
Recovery & Repair
TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a naturally occurring protein found in virtually all human and animal cells. The published research on Thymosin Beta-4 and its fragment is substantial — covering cardiac repair, wound healing, cellular migration, and anti-inflammatory activity.
Thymosin Beta-4 and Cardiac Repair — Activation of Epicardial Progenitor Cells
PubMed
Landmark Nature study demonstrating Thymosin Beta-4's ability to activate dormant epicardial progenitor cells after myocardial infarction in animal models. Researchers found significant cardiac tissue regeneration and functional improvement. This study established TB4's potential in cardiac repair research and generated substantial follow-on research interest.
Thymosin Beta-4 Accelerates Wound Healing — Actin Regulation and Cell Migration
PubMed
Reviews Thymosin Beta-4's role in wound healing through actin sequestration and regulation of cell motility. The research establishes the mechanism by which TB4 promotes cellular migration to injury sites — a key proposed mechanism for TB-500's systemic recovery activity.
Anti-Inflammatory Activity of Thymosin Beta-4 — Systemic Effects and Inflammatory Marker Reduction
PubMed
Examines Thymosin Beta-4's anti-inflammatory properties in multiple preclinical models. Researchers documented significant reduction in inflammatory markers and modulation of the inflammatory response across tissue types. Results supported further investigation of Tβ4 in inflammatory disease models.
Researching BPC-157 or TB-500?Verified supply with published third-party CoA available at ReViaLife — Florida 503(b) manufactured, endotoxin tested, 99%+ purity.
View Verified Source →
Semaglutide & GLP-1 Research
Metabolic Research
GLP-1 receptor agonists have the most substantial published research of any peptide category — including multiple large-scale human clinical trials with thousands of participants. The citations below represent landmark studies and regulatory documents from the most-researched metabolic compound category in current literature.
SUSTAIN-6 Trial — Cardiovascular Outcomes with Semaglutide in Type 2 Diabetes
Clinical Trial
Landmark NEJM trial examining cardiovascular outcomes in 3,297 patients with type 2 diabetes treated with semaglutide. Found significant reduction in major adverse cardiovascular events versus placebo. This trial was instrumental in establishing semaglutide's metabolic and cardiovascular research profile and led to its FDA approval for cardiovascular risk reduction.
STEP 1 Trial — Once-Weekly Semaglutide in Obesity Without Diabetes
Clinical Trial
Phase 3 trial in 1,961 adults with obesity (no diabetes). Semaglutide treatment produced mean body weight reduction of 14.9% versus 2.4% in placebo group. This trial generated widespread attention and contributed directly to semaglutide becoming the most-searched metabolic research compound globally. Results published in NEJM.
Discovery and Characterization of GLP-1 — The Incretin Effect
PubMed
Comprehensive review of GLP-1 biology by one of the field's primary researchers. Covers GLP-1 discovery, secretion mechanisms, metabolic effects, and the incretin effect. Establishes the foundational science underlying all GLP-1 agonist research. Widely cited — over 2,500 citations in scientific literature.
FDA Drug Approval — Semaglutide (Ozempic, Wegovy) Regulatory Documentation
FDA
Official FDA approval documentation for semaglutide pharmaceutical products. Ozempic approved for type 2 diabetes management (2017). Wegovy approved for chronic weight management (2021). These approvals established the pharmaceutical regulatory framework for semaglutide while research-grade semaglutide remains a separate, non-pharmaceutical research compound.
Tirzepatide Research
Metabolic Research · Dual Agonist
Tirzepatide — the GIP/GLP-1 dual agonist — has demonstrated some of the most significant metabolic research findings in recent clinical history. Its dual mechanism produces a distinct metabolic profile from GLP-1 agonism alone.
SURMOUNT-1 Trial — Tirzepatide for the Treatment of Obesity
Clinical Trial
Phase 3 trial in 2,539 adults with obesity. The highest tirzepatide dose (15mg weekly) produced mean body weight reduction of 20.9% versus 3.1% in placebo. These results were the most significant body composition findings in metabolic peptide clinical research at the time of publication and drove substantial research and commercial interest in dual agonism.
Tirzepatide — A Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
PubMed
Phase 3 SURPASS-2 trial comparing tirzepatide to semaglutide in type 2 diabetes management. Tirzepatide demonstrated superior HbA1c reduction and body weight reduction versus semaglutide, establishing the clinical distinction between dual and single receptor agonism in metabolic research.
CJC-1295 & Ipamorelin Research
GH Axis · Performance
CJC-1295 and Ipamorelin represent the most studied GH axis compound pairing in research literature. Research covers their individual and combined effects on GH secretion, IGF-1 levels, and downstream body composition effects.
CJC-1295 — A Long-Acting GHRH Analog that Increases GH and IGF-1 in Healthy Adults
Clinical Trial
Clinical study in 65 healthy adults demonstrating that CJC-1295 produced dose-dependent increases in mean plasma GH concentrations 2–10 fold and IGF-1 levels 1.5–3 fold, sustained for 6+ days after a single dose. This established the pharmacokinetic profile that makes CJC-1295 distinct from earlier, shorter-acting GHRH analogs.
Ipamorelin — A New Growth Hormone Secretagogue with Selective GH Release
PubMed
Foundational study establishing ipamorelin's pharmacological profile. Researchers demonstrated that ipamorelin releases GH with high potency and selectivity — without the significant cortisol, prolactin, or ACTH release seen in older GHRPs like GHRP-2 and GHRP-6. This selectivity profile made ipamorelin the preferred GHRP for GH axis research.
GHK-Cu Research
Longevity · Cosmetic · Skin Biology
GHK-Cu — A Copper Peptide with Extraordinary Regenerative and Anti-Aging Properties
PubMed
Comprehensive review of GHK-Cu's biological activity. Documents its stimulation of collagen synthesis, wound healing properties, anti-inflammatory and antioxidant activity, and gene expression analysis showing GHK-Cu resets gene expression in aging skin toward a younger biological state. Includes analysis of over 4,000 human genes modulated by GHK-Cu.
Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging
PubMed
Reviews GHK-Cu's role in preventing oxidative stress and degenerative aging processes. Research documents its effects on collagen production, wound repair, and broad anti-aging gene activation. Notes significant decline in plasma GHK-Cu levels with age as a driver of research interest in supplemental study.
FDA Documentation & Regulatory References
Regulatory Framework
Official FDA documentation covering drug approval processes, compounding regulations, research use designations, and relevant regulatory actions affecting the research compound space.
FDA Drug Development and Approval Process — Official Overview
FDA
Official FDA documentation explaining the pharmaceutical drug development and approval process — IND application, Phase I-III clinical trials, NDA submission, and post-market surveillance. This framework explains why research compounds exist outside pharmaceutical approval while legitimate research continues — the process costs $1B+ and takes 10-15 years per compound.
FDA 503B Outsourcing Facilities — Regulatory Requirements and Oversight
FDA
Official FDA documentation on 503B outsourcing facilities — the regulatory category that defines the highest standard of accountability for compounded and research compounds in the US. Covers cGMP requirements, FDA inspection protocols, registration requirements, and quality standards. This is the standard ReViaLife's manufacturing partner meets.
Current Good Manufacturing Practice (cGMP) Regulations — FDA Official Guidance
FDA
The federal regulations defining cGMP standards for pharmaceutical manufacturing. Covers facility requirements, quality systems, production controls, laboratory controls, and record-keeping. These are the rules that cGMP-certified facilities must follow — and the standard against which ReViaWell evaluates supplier manufacturing claims.
FDA Guidance — Research Use Only Products and Investigational Use Products
FDA
FDA guidance document explaining the Research Use Only designation — what it means, what restrictions apply, and how RUO products differ from FDA-approved medical devices and drugs. Establishes the legal framework under which research compounds are legitimately sold and studied in the United States.
Manufacturing Standards & Quality Research
cGMP · Endotoxin · Purity Standards
USP General Chapter 85 — Bacterial Endotoxins Test (LAL Testing Standards)
USP / NIH
The official United States Pharmacopeia standard for bacterial endotoxin testing using the Limulus Amebocyte Lysate (LAL) method. This is the gold standard testing protocol that pharmaceutical-grade manufacturing uses for endotoxin screening — and the standard referenced when evaluating whether a peptide supplier's CoA includes legitimate endotoxin testing results.
ICH Q2(R1) — Validation of Analytical Procedures: Text and Methodology (HPLC Standards)
ICH / FDA
The international pharmaceutical standard for analytical method validation — including HPLC purity testing. This guideline defines what constitutes a validated HPLC method for pharmaceutical-grade purity determination. Understanding this standard helps evaluate whether a supplier's HPLC testing meets the quality threshold required for research compound verification.
Adulteration and Contamination in the Research Chemical and Supplement Market — Independent Analysis
PubMed
Multiple peer-reviewed analyses have documented the prevalence of adulteration, mislabeling, and contamination in the research chemical and supplement markets. Independent testing programs have found significant discrepancies between labeled and actual content, contamination with undisclosed substances, and failure to meet stated purity specifications across categories including peptides and research compounds.
Market & Industry Data
Market Research · Industry Analysis
Global Peptide Therapeutics Market — Size, Growth, and Forecast Analysis
Market Research
Multiple independent market research firms project the global peptide therapeutics market to exceed $50 billion by 2026–2028, with compound annual growth rates of 7–9%. Growth is driven by GLP-1 agonist adoption, expanding metabolic disease research, longevity science investment, and increasing biopharmaceutical pipeline activity. The growth of the therapeutic market drives corresponding growth in research compound interest.
PubMed Database — Peptide Research Publication Volume and Growth Trends
NIH / PubMed
The PubMed database currently indexes over 5,000 studies examining research peptide mechanisms, with publication rates increasing year-over-year as metabolic, longevity, and recovery research gains mainstream scientific interest. Searches for "BPC-157" return 300+ indexed studies. "Semaglutide" returns 3,000+ studies. "GLP-1 receptor agonist" returns 12,000+ indexed publications.
Key News Coverage & Institutional Reporting
Media · Institutional · Policy
Significant mainstream news coverage and institutional reporting that shaped public awareness of peptide research and the regulatory landscape.
The Ozempic Era — How a Diabetes Drug Became the World's Most Talked-About Medicine
News / Media
Major publications including the NYT, WSJ, and The Economist published extensive coverage of semaglutide's mainstream emergence as Ozempic became a cultural phenomenon. This coverage drove the largest single surge in public interest in GLP-1 compounds and peptide research broadly, bringing the research compound space into mainstream awareness.
RFK Jr. as HHS Secretary — Health Freedom Policy and Research Compound Implications
Policy / News
Coverage of Robert F. Kennedy Jr.'s confirmation as HHS Secretary and his stated policy positions on FDA reform, research compound access, and pharmaceutical industry oversight. Multiple outlets reported on implications for peptide research compound regulation, including renewed discussion of BPC-157's compounding status and broader research access policy.
The Longevity Movement — How Silicon Valley and Biohackers Mainstreamed Peptide Research
News / Media
Coverage of the longevity and biohacking movement's adoption of research peptides — particularly BPC-157, TB-500, GHK-Cu, and GH axis compounds — and how tech industry figures and biohacking communities brought these compounds into mainstream wellness conversation. This coverage significantly expanded the research compound market beyond traditional bodybuilding communities.
Get the full research library — free.
85+ compounds with plain-English explanations, the supplier verification checklist, and 6 in-depth research guides. Everything referenced on this page — explained in plain English.
✓ Check your inbox — access is on the way.
For adults 21+. Research use only. No spam. Unsubscribe anytime.